Navigation Links
Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
Date:12/7/2010

curities Litigation Reform Act of 1995, and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs.  The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements.  These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission including the risks under the headings: "Regulatory authorities may not approve our product candidates even if they meet safety and efficacy endpoints in clinical trials.", "We have a history of net losses. We expect to continue to incur substantial and increasing net losses for the foreseeable future, and we may never achieve or maintain profitability.", and "We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.".  Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Inc. (NASDAQ: UPI ), a medical device ... products to treat voiding dysfunctions, today reported financial ... 30, 2014.  Global revenue for the ... to $4.1 million, as compared to $3.4 million ... Total revenue for the fiscal first quarter of ...
(Date:7/24/2014)... -- Mettler-Toledo International Inc. (NYSE: MTD ) today ... the highlights: , Sales in local currency ... prior year. Reported sales increased 5% which included a ... diluted share as reported (EPS) were $2.49, compared with ... was $2.57, an increase of 9% over the prior-year ...
(Date:7/24/2014)... , July 24, 2014 Amgen (NASDAQ: ... second quarter financial results on Tuesday, July 29, 2014, after ... be followed by a conference call with the investment community ... will be Robert A. Bradway , chairman and chief ... Live audio of the conference call will be ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... 2011 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... the second quarter 2011 prior to the open of the ... H. Johnson, Chief Executive Officer and President, and David Gionco, ... investment community conference call beginning at 9:00 a.m. Eastern Time ...
... Accuray Incorporated (Nasdaq: ARAY ), ... symposium examining best practices for quality assurance in ... of Physicists in Medicine (AAPM)/Canadian Organization of Medical ... Programs for Today,s Radiation Oncology Platforms "—will discuss ...
Cached Medicine Technology:Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011 2Accuray Hosts Symposium on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting 2
(Date:7/25/2014)... July 25, 2014 ZeptoMetrix™ Corporation ... reliable and trusted products and services for infectious ... release of NATtrol™ RP Multimarker Controls - ... in vitro diagnostic, CE marked, unassayed external run ... assays the NATtrol™ RP Multimarker Controls - MDZ001 ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Healthpointe ... Mirada clinic is offering Occupational Medicine services ... is happily accepting referrals and workers’ compensation cases. ... La Mirada clinic include wound care treatment management, ... ergonomic assessments, pre-employment screening & physicals, and illness ...
(Date:7/25/2014)... Vegas, NV (PRWEB) July 25, 2014 ... the one day Online Workshop ‘Consciousness is Power’ on ... globe are invited to attend this life transforming event ... consciousness to a higher level. Few days are left ... this workshop, Mahendra Trivedi and Trivedi Masters™ Dahryn Trivedi ...
(Date:7/25/2014)... FL (PRWEB) July 25, 2014 iTanSmart ... iPods, and iPads. The app provides a tailored approach ... and potentially dangerous sunburns and skin damage. In his ... sights, sounds, and capabilities of iTanSmart. , Eaton ... the app as a ‘better organized’ and ‘great alternative’ ...
(Date:7/25/2014)... Tampa, FL (PRWEB) July 25, 2014 ... launches their innovative toothbrushes with antibacterial silver that naturally kill ... land on the brush. , A toothbrush is the ... diseases, dental health and hygiene, however, it is subject to ... the air. , There are more bacteria in the mouth ...
Breaking Medicine News(10 mins):Health News:ZeptoMetrix™ Corporation (ZMC) Releases FDA Class 1 Exempt, IVD and CE Labeled NATtrol™ RP Multimarker Controls 2Health News:Healthpointe Offering Occupational Medicine Services in La Mirada 2Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 2Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 3Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 2Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 3
... a research news published says, in people with mild ... and about halve the dose of preventer inhaler//. ... breathing techniques on symptoms, lung function, use of medication ... asthma. ,One technique focused on shallow, nasal ...
... of Australia(COSA), which conducted a review of country hospitals ... little or no training, to administer chemotherapy to ... posed a risk to these patients. ... that the patient (might) be under-dosed, so they have ...
... researchers from The Institute for Genomic Research, (TIGR), in Maryland, ... in the GI system, stated that we may not be ... by studying the bacteria that are always present in our ... and as to how certain drugs could work on certain ...
... survey conducted by UNAIDS has put India on par with ... have the highest estimated number of HIV infected people//. ... the UNAIDS 2006 Report on the Global AIDS Epidemic is ... adults above 49 years of age whereupon the Indian HIV ...
... the second highest success rate in heart surgeries, ensuring that ... success stories, the group's chairman Prathap C Reddy said here ... celebration, he said while the hospital that had the highest ... more cost effective as it charged less than 4,000 dollars. ...
... Making an about-turn, Delhi's Apollo Hospital today disclosed that traces ... sample of Rahul Mahajan//, a day after its doctors had ... tested negative for all known drugs. ,'Traces of ... Since its cocktail of drugs, we cannot conclusively say which ...
Cached Medicine News:Health News:Humans, A Symbiotic Organisms Dependent On Other Life Forms For Existence 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: